Clinical trials: Malignant Disease
Bone Metastases
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
The goal of this clinical trial was to assess the diagnostic performance and safety of Sodium Fluoride F-18 Positron Emission Tomography / Computed Tomography (18F-NaF-PET/CT) in bone metastases of malignant tumors compared with…
- Trial name
- NCT05614518
- Testing
- Sodium Fluoride F-18 Injection, Technetium[99mTc] Methylenediphosphonate Injection
- Where
- China
- Volunteers
- 280 people
- Sponsor
- HTA Co., Ltd.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Duodenal Obstruction, Gastric Outlet Obstruction
EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms
The objective of this investigation is to compile clinical experience on the use of the Evolution® Duodenal Stent (Cook Ireland), a CE marked device intended for the palliative treatment of duodenal or gastric outlet obstruction…
- Trial name
- NCT00991614
- Testing
- EVOLUTION® Duodenal Stent
- Where
- 6 sites in Australia, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Cook Group Incorporated
Melanoma Recurrent, Malignant Melanoma
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
This is an open label Pilot study to evaluate the combination of Vigil™ and pembrolizumab in patients with incurable locally advanced or metastatic melanoma.
- Conditions
- Melanoma Recurrent, Malignant Melanoma, Melanoma
- Trial name
- NCT02574533
- Testing
- Vigil, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Gradalis, Inc.
Lung Cancer, Mesothelioma
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
The purpose of this study is to evaluate the safety, and tissue effect of the CryoSpray Ablation(TM) System (CryoSpray Ablation(TM), "CSA" or "cryospray therapy") at multiple centers to treat malignant airway disease in the lung…
- Trial name
- ICEtheMAD (NCT00748085)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
- Trial name
- NCT04749485
- Testing
- HX008
- Where
- 11 sites in China
- Volunteers
- 119 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Glioblastoma, Glioblastoma Multiforme
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
This phase I trial investigates the efficacy and safety of brain-targeting epidermal growth factor receptor chimeric antigen receptor immune cells (EGFRvIII-CAR T cells) in treating patients with leptomeningeal disease from…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant
- Trial name
- CARTREMENDOUS (NCT05063682)
- Testing
- EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
- Where
- 3 sites in Finland, India
- Volunteers
- 10 people
- Sponsor
- Chembrain LTD
Melanoma
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
The primary objective of this extension study was to further assess the safety and tolerability of talimogene laherparepvec. Secondary objectives were to assess objective tumor response rate and survival.
- Trial name
- NCT02574260
- Testing
- Talimogene Laherparepvec
- Volunteers
- 3 people
- Sponsor
- BioVex Limited
Melanoma
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment.
- Trial name
- CALMext (NCT01636882)
- Testing
- CVA21
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Viralytics
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumours, Cervical Cancer
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.
- Conditions
- Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma
- Trial name
- NCT03852823
- Testing
- SG001
- Where
- China
- Volunteers
- 192 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Malignant Neoplasm, Malignant Neoplasm of Brain
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise.
- Trial name
- NCT06012695
- Testing
- NBM-BMX Capsule, Temozolomide, Standard radiotherapy
- Where
- 4 sites in Taiwan
- Volunteers
- 79 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Mesothelioma
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma.
- Trial name
- ATOMIC (NCT02709512)
- Testing
- ADI-PEG 20 plus Pem Platinum
- Where
- 45 sites in United States, Australia and 3 more
- Volunteers
- 249 people
- Sponsor
- Polaris Group
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Malignant Melanoma
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
This open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and efficacy of vemurafenib (RO5185426) in pediatric…
- Trial name
- NCT01519323
- Testing
- vemurafenib
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Cancer, Malignant Melanoma
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
- Trial name
- NCT00601861
- Testing
- recombinant interleukin-21
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Novo Nordisk A/S
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Opioid-induced Constipation
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.
- Trial name
- NCT01443403
- Testing
- Naldemedine
- Where
- 49 sites in United States
- Volunteers
- 244 people
- Sponsor
- Shionogi